Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy

Sara Caporuscio, Roberto Ieraci, Guido Valesini, Raffaela Teloni, Sabrina Mariotti, Francesca Romana Spinelli, Claudia Ferlito, Simonetta Salemi, Andrea Picchianti Diamanti, Giorgia Meneguzzi, Milica Markovic, Mayla Sgrulletti, Christina von Hunolstein, Luisa Ralli, Antonietta Pinto, Gerardo Salerno, Marco Canzoni, Maria Laura Sorgi, Bruno Laganà, Roberta Di RosaRoberto Nisini, Raffaele D'Amelio

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Immunogenicity of 13-valent pneumococcal polysaccharide (PnPS) conjugate vaccine (PCV13) was evaluated in 38 rheumatoid arthritis patients under immunosuppressive treatment and 20 healthy controls (HC). Antibodies to all PnPS and diphtheria-toxin analogue conjugate protein were measured pre- (T0), 1 (T1), 6 (T2), 12 (T3) months post-immunization. Patients and HC had similar response to individual PnPS. Mean antibody levels to all PnPS but one doubled at T1 compared with T0, with T3 persistence for only 8-7/13 PnPS. Baseline antibody levels was inversely associated with the rate of responders at T1 (T1/T0≥2) to 11/13 PnPS. Few subjects reached protective IgG levels against some serotypes frequently isolated in Italian patients with invasive pneumococcal disease. Antibody response was not influenced by therapy, except the one to PS7F, which was reduced by tumor necrosis factor-α-inhibitors. Vaccination increased also anti-diphtheria IgG. Despite this study substantially confirmed the PCV13 immunogenicity in immunocompromised patients, it also revealed some limitations.

Original languageEnglish
Pages (from-to)18-27
Number of pages10
JournalClinical Immunology
Volume195
DOIs
Publication statusPublished - Oct 1 2018

Fingerprint

Diphtheria
Immunosuppressive Agents
Polysaccharides
Rheumatoid Arthritis
Vaccination
Antibodies
Diphtheria Toxin
Therapeutics
Immunotoxins
Conjugate Vaccines
Pneumococcal Vaccines
Immunocompromised Host
Antibody Formation
Immunization
Tumor Necrosis Factor-alpha
Immunoglobulin G
Proteins

Keywords

  • 13-valent pneumococcal conjugate vaccine
  • Antibody persistence
  • Immunogenicity
  • Immunosuppressive therapy
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy. / Caporuscio, Sara; Ieraci, Roberto; Valesini, Guido; Teloni, Raffaela; Mariotti, Sabrina; Spinelli, Francesca Romana; Ferlito, Claudia; Salemi, Simonetta; Picchianti Diamanti, Andrea; Meneguzzi, Giorgia; Markovic, Milica; Sgrulletti, Mayla; von Hunolstein, Christina; Ralli, Luisa; Pinto, Antonietta; Salerno, Gerardo; Canzoni, Marco; Sorgi, Maria Laura; Laganà, Bruno; Di Rosa, Roberta; Nisini, Roberto; D'Amelio, Raffaele.

In: Clinical Immunology, Vol. 195, 01.10.2018, p. 18-27.

Research output: Contribution to journalArticle

Caporuscio, S, Ieraci, R, Valesini, G, Teloni, R, Mariotti, S, Spinelli, FR, Ferlito, C, Salemi, S, Picchianti Diamanti, A, Meneguzzi, G, Markovic, M, Sgrulletti, M, von Hunolstein, C, Ralli, L, Pinto, A, Salerno, G, Canzoni, M, Sorgi, ML, Laganà, B, Di Rosa, R, Nisini, R & D'Amelio, R 2018, 'Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy', Clinical Immunology, vol. 195, pp. 18-27. https://doi.org/10.1016/j.clim.2018.07.010
Caporuscio, Sara ; Ieraci, Roberto ; Valesini, Guido ; Teloni, Raffaela ; Mariotti, Sabrina ; Spinelli, Francesca Romana ; Ferlito, Claudia ; Salemi, Simonetta ; Picchianti Diamanti, Andrea ; Meneguzzi, Giorgia ; Markovic, Milica ; Sgrulletti, Mayla ; von Hunolstein, Christina ; Ralli, Luisa ; Pinto, Antonietta ; Salerno, Gerardo ; Canzoni, Marco ; Sorgi, Maria Laura ; Laganà, Bruno ; Di Rosa, Roberta ; Nisini, Roberto ; D'Amelio, Raffaele. / Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy. In: Clinical Immunology. 2018 ; Vol. 195. pp. 18-27.
@article{8b59e79feba04cd0b889a726f5471e36,
title = "Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy",
abstract = "Immunogenicity of 13-valent pneumococcal polysaccharide (PnPS) conjugate vaccine (PCV13) was evaluated in 38 rheumatoid arthritis patients under immunosuppressive treatment and 20 healthy controls (HC). Antibodies to all PnPS and diphtheria-toxin analogue conjugate protein were measured pre- (T0), 1 (T1), 6 (T2), 12 (T3) months post-immunization. Patients and HC had similar response to individual PnPS. Mean antibody levels to all PnPS but one doubled at T1 compared with T0, with T3 persistence for only 8-7/13 PnPS. Baseline antibody levels was inversely associated with the rate of responders at T1 (T1/T0≥2) to 11/13 PnPS. Few subjects reached protective IgG levels against some serotypes frequently isolated in Italian patients with invasive pneumococcal disease. Antibody response was not influenced by therapy, except the one to PS7F, which was reduced by tumor necrosis factor-α-inhibitors. Vaccination increased also anti-diphtheria IgG. Despite this study substantially confirmed the PCV13 immunogenicity in immunocompromised patients, it also revealed some limitations.",
keywords = "13-valent pneumococcal conjugate vaccine, Antibody persistence, Immunogenicity, Immunosuppressive therapy, Rheumatoid arthritis",
author = "Sara Caporuscio and Roberto Ieraci and Guido Valesini and Raffaela Teloni and Sabrina Mariotti and Spinelli, {Francesca Romana} and Claudia Ferlito and Simonetta Salemi and {Picchianti Diamanti}, Andrea and Giorgia Meneguzzi and Milica Markovic and Mayla Sgrulletti and {von Hunolstein}, Christina and Luisa Ralli and Antonietta Pinto and Gerardo Salerno and Marco Canzoni and Sorgi, {Maria Laura} and Bruno Lagan{\`a} and {Di Rosa}, Roberta and Roberto Nisini and Raffaele D'Amelio",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.clim.2018.07.010",
language = "English",
volume = "195",
pages = "18--27",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy

AU - Caporuscio, Sara

AU - Ieraci, Roberto

AU - Valesini, Guido

AU - Teloni, Raffaela

AU - Mariotti, Sabrina

AU - Spinelli, Francesca Romana

AU - Ferlito, Claudia

AU - Salemi, Simonetta

AU - Picchianti Diamanti, Andrea

AU - Meneguzzi, Giorgia

AU - Markovic, Milica

AU - Sgrulletti, Mayla

AU - von Hunolstein, Christina

AU - Ralli, Luisa

AU - Pinto, Antonietta

AU - Salerno, Gerardo

AU - Canzoni, Marco

AU - Sorgi, Maria Laura

AU - Laganà, Bruno

AU - Di Rosa, Roberta

AU - Nisini, Roberto

AU - D'Amelio, Raffaele

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Immunogenicity of 13-valent pneumococcal polysaccharide (PnPS) conjugate vaccine (PCV13) was evaluated in 38 rheumatoid arthritis patients under immunosuppressive treatment and 20 healthy controls (HC). Antibodies to all PnPS and diphtheria-toxin analogue conjugate protein were measured pre- (T0), 1 (T1), 6 (T2), 12 (T3) months post-immunization. Patients and HC had similar response to individual PnPS. Mean antibody levels to all PnPS but one doubled at T1 compared with T0, with T3 persistence for only 8-7/13 PnPS. Baseline antibody levels was inversely associated with the rate of responders at T1 (T1/T0≥2) to 11/13 PnPS. Few subjects reached protective IgG levels against some serotypes frequently isolated in Italian patients with invasive pneumococcal disease. Antibody response was not influenced by therapy, except the one to PS7F, which was reduced by tumor necrosis factor-α-inhibitors. Vaccination increased also anti-diphtheria IgG. Despite this study substantially confirmed the PCV13 immunogenicity in immunocompromised patients, it also revealed some limitations.

AB - Immunogenicity of 13-valent pneumococcal polysaccharide (PnPS) conjugate vaccine (PCV13) was evaluated in 38 rheumatoid arthritis patients under immunosuppressive treatment and 20 healthy controls (HC). Antibodies to all PnPS and diphtheria-toxin analogue conjugate protein were measured pre- (T0), 1 (T1), 6 (T2), 12 (T3) months post-immunization. Patients and HC had similar response to individual PnPS. Mean antibody levels to all PnPS but one doubled at T1 compared with T0, with T3 persistence for only 8-7/13 PnPS. Baseline antibody levels was inversely associated with the rate of responders at T1 (T1/T0≥2) to 11/13 PnPS. Few subjects reached protective IgG levels against some serotypes frequently isolated in Italian patients with invasive pneumococcal disease. Antibody response was not influenced by therapy, except the one to PS7F, which was reduced by tumor necrosis factor-α-inhibitors. Vaccination increased also anti-diphtheria IgG. Despite this study substantially confirmed the PCV13 immunogenicity in immunocompromised patients, it also revealed some limitations.

KW - 13-valent pneumococcal conjugate vaccine

KW - Antibody persistence

KW - Immunogenicity

KW - Immunosuppressive therapy

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=85050367427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050367427&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2018.07.010

DO - 10.1016/j.clim.2018.07.010

M3 - Article

AN - SCOPUS:85050367427

VL - 195

SP - 18

EP - 27

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

ER -